Diffuse large B cell lymphoma(DLBCL)is one of the most prevalent lymphoid malignancies.The current standard of care can cure about two-thirds of DLBCL patients.1 Primary testicular diffuse large B-cell lymphoma(PT-DLB...Diffuse large B cell lymphoma(DLBCL)is one of the most prevalent lymphoid malignancies.The current standard of care can cure about two-thirds of DLBCL patients.1 Primary testicular diffuse large B-cell lymphoma(PT-DLBCL)is a rare but highly aggressive form of mature B-cell lymphoma that accounts for approximately 1%-9%of testicular malignancies.Different from nodal DLBCL,PT-DLBCL has a markedly worse prognosis because of inferior response to the current treatment regimens and significant extranodal tropism.2 Three main questions remained unresolved in the field of PT-DLBCL research.展开更多
基金supported by grants from the National Natural Science Foundation of China,China(No.82072638 to Y.Z.and No.81602222 to H.S.)the Biobank Program of Shanghai Ninth People's Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai,China(No.YBKB202217 to Y.Z.).
文摘Diffuse large B cell lymphoma(DLBCL)is one of the most prevalent lymphoid malignancies.The current standard of care can cure about two-thirds of DLBCL patients.1 Primary testicular diffuse large B-cell lymphoma(PT-DLBCL)is a rare but highly aggressive form of mature B-cell lymphoma that accounts for approximately 1%-9%of testicular malignancies.Different from nodal DLBCL,PT-DLBCL has a markedly worse prognosis because of inferior response to the current treatment regimens and significant extranodal tropism.2 Three main questions remained unresolved in the field of PT-DLBCL research.
